RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system

JOURNAL OF CONTROLLED RELEASE

卷:173

Article

Sakurai, Yu¹  Hatakeyama, Hiroto¹  Sato, Yusuke¹  Hyodo, Mamoru¹  Akita, Hidetaka¹  Ohga, Noritaka²  Hida, Kyoko²  Harashima, Hideyoshi¹ 

[1] Hokkaido Univ, Fac Pharmaceut Sci, Lab Innovat Nanomed, Kita Ku, Sapporo, Hokkaido 0600812, Japan

[2] Hokkaido Univ, Grad Sch Dent Med, Div Vasc Biol, Kita Ku, Sapporo, Hokkaido 0600812, Japan

关键词: siRNA;    Liposome;    Anti-angiogenic therapy;    Cyclic RGD;    Active targeting;   

DOI  :  10.1016/j.jconrel.2013.10.003

来源: Elsevier

【 摘 要 】

Angiogenesis is one of crucial processes associated with tumor growth and development, and consequently a prime target for cancer therapy. Although tumor endothelial cells (TECs) play a key role in pathological angiogenesis, investigating phenotypical changes in neovessels when a gene expression in TEC is suppressed is a difficult task. Small interfering RNA (siRNA) represents a potential agent due to its ability to silence a gene of interest. We previously developed a system for in vivo siRNA delivery to cancer cells that involves a liposomal-delivery system, a MEND that contains a unique pH-sensitive cationic lipid, YSK05 (YSK-MEND). In the present study, we report on the development of a system that permits the delivery of siRNA to TECs by combining the YSK-MEND and a ligand that is specific to TECs. Cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGD) is a well-known ligand to alpha(V)beta(3) integrin, which is selectively expressed at high levels in TECs. We incorporated cRGD into the YSK-MEND (RGD-MEND) to achieve an efficient gene silencing in TECs. Quantitative RT-PCR and the 5' rapid amplification of cDNA ends PCR indicated that the intravenous injection of RGD-MEND at a dose of 4.0 mg/kg induced a significant RNAi-mediated gene reduction in TEC but not in endothelial cells of other organs. Finally, we evaluated the therapeutic potency of the RGD-MEND encapsulating siRNA against vascular endothelial growth factor receptor 2. A substantial delay in tumor growth was observed after three sequential RGD-MEND injections on alternate days. In conclusion, the RGD-MEND represents a new approach for the characterization of TECs and for us in anti-angiogenic therapy. (C) 2013 Elsevier B.V. All rights reserved.

【 授权许可】

Free